Searching…
Nov 14, 2023 · ORION-18 (Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease [ASCVD] or ASCVD High Risk and Elevated Low-Density Lipoprotein Cholesterol [LDL-C]...
Mar 18, 2020 · Antidrug antibodies were detected in 2.0% and 2.5% of the samples from inclisiran-treated patients in the ORION-10 and ORION-11 trials, respectively, findings consistent with assay specifications ...
2025年2月，《中国循环杂志》正式发表ORION-18研究中国大陆亚组分析结果。 该研究首次聚焦新型小干扰RNA（siRNA）降脂药物英克司兰（Inclisiran）在中国动脉粥样硬化性心血管疾病（ASCVD）患者及高危人群中的疗效与安全性。
The aim of this study was to assess the effect of long-term dosing of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol. Methods: ORION-3 was a 4-year open-label extension study of the ...
Jan 20, 2023 · ORION-3研究已经在ClinicalTrials.gov网站注册，注册号为NCT03060577。 研究结果 ORION-1研究队列最初包含497名受试者，2017年3月24日至2021年12月17日ORION-3研究进行期间， inclisiran组370名患者中有290人继续参与研究成为仅inclisiran治疗组，安慰剂组127名患者中有92人成为换药组。
What did ORION-8 look at? ORION-8 assessed the efficacy and safety of inclisiran when used long-term in patients with high risk of cardiovascular events (detailed in table below) and elevated LDL-C levels despite taki...
There are an estimated 7 million people living with cardiovascular disease in the UK. ORION-4 is a randomised controlled trial testing a new medicine called inclisiran. Inclisiran helps to lower bad (LDL) cholesterol....
Sep 1, 2023 · 对于备受临床关注的长期疗效和安全性问题，在继Ⅱ期ORION-3扩展研究取得良好结果之后，ESC 2023会议公布的ORION-8研究，报告了英克司兰治疗最长超过 ...
Aug 9, 2010 · 本项研究虽并未能确定英克司兰是否会减少心血管事件，但其展现的英克司兰长期安全性同样令人鼓舞，后续ORION-4、VICTORION-2P和VICTORION-1P三项大型临床研究将进一步揭晓英克司兰对硬性心血管结局的影响。
Sep 8, 2023 · ESC 2023会议公布了ORION-8长期随访研究的结果，探讨了这一话题。 ORION-8研究是对ORION-3，ORION-9，ORION-10和ORION-11的RCT试验患者的汇总延长随访分析。 后三项是安慰剂对照RCT试验，共纳入了3,660名患者，随访时间为18个月。
